Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Leukemia: Lymphoid leukemia

A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to compare the effects, both good and bad, that two different cancer treatments have on patients and their cancer. These treatments include combinations of the drugs rituximab, fludarabine, cyclophosphamide and ibrutinib.

Status: Accepting New Patients
Principal Investigator: Shuo Ma

The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

The overall purpose of this study is to determine if JCAR015 is effective at getting rid of leukemia cells from the blood and bone marrow and putting participants with relapsed B cell ALL into a complete remission (no visible leukemia in the bone marrow).

Status: Accepting New Patients
Principal Investigator: Shira Dinner

A Randomized, Parallel-Cohort Phase 1 Study of INCB039110 in Combination With Corticosteroids for the Treatment of Grades II to IV Acute Graft-Versus-Host Disease

The purpose of this study is to assess the safety and tolerability of INCB039110 in combination with corticosteroids in subjects with Grades II to IV acute graft-versus-host disease (GVHD).

Status: Accepting New Patients
Principal Investigator: John Galvin

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

The purpose of this study is to evaluate the effect of ABT-199 (GDC-0199)on CLL that has come back or did not get better after B-cell Receptor Signaling Pathway Inhibitor (BCR PI)treatment.

Status: Accepting New Patients
Principal Investigator: Shuo Ma

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

The purpose of this research is to evaluate the safety and tolerability of the investigational drug, INCB053914, and to select the doses that will be studied further in people with advanced cancers or diseases where cells grow too much.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

The purpose of this study is to learn about the safety of SD-101 and to find out what effects (both good and bad it has on B-cell Lymphoma when given along with low-dose radiation therapy.

Status: Accepting New Patients
Principal Investigator: Leo Gordon

A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia

The purpose of this study is to evaluate the safety of an investigational drug, CB-839, and to determine the best dose to use for future studies.

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Young Chae

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer

The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.

Status: Accepting New Patients
Principal Investigator: Jeffrey Raizer

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Tue - May 24, 2016 - 08:05 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.